Biomarkers used to predict response include tumor burden, PD-1 expression balance between effector and regulatory T cells in tumor microenvironment, PD-L1 expression by the tumor cells, and composition of the gut microbiota (4–7). This evidence concerns the gene PDCD1 and neoplasm.